Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 11/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | NHERF1 | O14745 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6368987 | 0.90 | NHERF1 (0.56) | PYGLKMT2AMEN1RXFP1NHERF1 | |
| SCHEMBL6369118 | 0.86 | KMT2A (0.47) | PYGLKMT2AMEN1RXFP1NHERF1 | |
| SCHEMBL6373769 | 0.84 | HRH4 (0.58) | PYGLKMT2AMEN1RXFP1NHERF1 | |
| SCHEMBL6369837 | 0.83 | NHERF1 (0.51) | PYGLKMT2AMEN1RXFP1NHERF1 | |
| SCHEMBL6369723 | 0.80 | PYGL (0.52) | PYGLKMT2AMEN1RXFP1NHERF1 | |
| SCHEMBL6369217 | 0.76 | NHERF1 (0.53) | PYGLKMT2AMEN1RXFP1NHERF1 | |
| SCHEMBL6376602 | 0.74 | NHERF1 (0.62) | PYGLKMT2AMEN1RXFP1NHERF1 | |
| SCHEMBL6369645 | 0.73 | POLB (0.55) | PYGLKMT2AMEN1RXFP1NHERF1 | |
| SCHEMBL6369643 | 0.73 | POLB (0.55) | PYGLKMT2AMEN1RXFP1NHERF1 | |
| SCHEMBL6772117 | 0.73 | NPC1 (0.71) | PYGLKMT2AMEN1RXFP1NHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | GAMMILL RONALD B (US) | 2005-01-27 | — | — | US | disclosed |
| US-6821977-B2 | SUBSTITUTED 1H-(INDOLE-2- CARBOXAMIDES AND 6H-THIENO(2,3-B)PYRROLE-5-CARBOXAMIDES USEFUL FOR INHIBITING GLYCOGEN PHOSPHORYLASE IN A MAMMAL | PFIZER, INC. | 2004-11-23 | — | — | US | disclosed |
| US-20030199553-A1 | Antidiabetic agents | GAMMILL RONALD B (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003072570-A1 | ANTIDIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-1340500-A1 | Antidiabetic agents | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199553-A1 | Antidiabetic agents | GPR119, IRS1, INSR | PYGL 75/4885KMT2A 4151/4885MEN1 1828/4885 |
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | PYGM, PYGL, IRS1 | PYGL 2/4885KMT2A 2347/4885MEN1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.